Last reviewed · How we verify
DFD-29
DFD-29 is a topical antimicrobial agent designed to treat bacterial skin infections by disrupting bacterial cell function.
DFD-29 is a topical antimicrobial agent designed to treat bacterial skin infections by disrupting bacterial cell function. Used for Bacterial skin infections (Phase 3).
At a glance
| Generic name | DFD-29 |
|---|---|
| Sponsor | Journey Medical Corporation |
| Drug class | Topical antimicrobial |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
DFD-29 is being developed by Journey Medical Corporation as a novel topical treatment for bacterial skin infections. The drug is formulated to provide enhanced antimicrobial activity against common skin pathogens. It is currently in Phase 3 clinical development for dermatological indications.
Approved indications
- Bacterial skin infections (Phase 3)
Common side effects
Key clinical trials
- A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) (PHASE3)
- A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. (PHASE3)
- Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks (PHASE1)
- A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects (PHASE1)
- A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFD-29 CI brief — competitive landscape report
- DFD-29 updates RSS · CI watch RSS
- Journey Medical Corporation portfolio CI